Literature DB >> 35149923

A Delphi study on the clinical management of age-related macular degeneration.

Nuno Gomes1, Angelina Meireles2, Ângela Carneiro3, Rufino Silva4,5,6, António Campos7,8, Lilianne Duarte9, Rita Flores10, Carlos Marques-Neves11.   

Abstract

PURPOSE: Age-related macular degeneration (AMD) is one of the main causes of blindness and visual impairment worldwide. As achieving a dry macula is one of the main objectives in AMD management, the purpose of this work was to reach a consensus on the relevance of retinal fluid in function, disease activity control and treatment patterns.
METHODS: Forty-seven Portuguese ophthalmologists specialized in AMD participated in a DELPHI panel. Two rounds of presential meetings were conducted and a cut-off of 80% or more of votes was defined to consider answers consensual.
RESULTS: Consensus was reached for 11 out of 18 questions. These questions focused on the impact of anatomical results on visual acuity, standards exams and parameters to assess disease activity, frequency and factors which influence disease activity assessment, criteria to use non-fixed treatment regimens, usefulness of individualized regimens and conditions for treatment interruption. No consensus was obtained for relevance of the different fluid types in AMD prognosis, frequency of fluid presence assessment, factors commonly associated with progression to geographic atrophy, ideal conditions for a fixed treatment regimen, date of first disease activity assessment and parameters to monitor disease activity.
CONCLUSIONS: Consensus was achieved for over half of the questions assessed through this Delphi study. The questions for which no consensus was reached concerned either subjects that need further investigation or monitoring times which are influenced by resource availability. Raising awareness for these issues will allow the improvement of AMD management and treatment.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Age-related macular degeneration; Consensus; Disease activity; Disease management; Retinal fluid; Treatment regimen

Mesh:

Year:  2022        PMID: 35149923     DOI: 10.1007/s10792-021-02177-2

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  37 in total

Review 1.  Age related macular degeneration.

Authors:  Amresh Chopdar; Usha Chakravarthy; Dinesh Verma
Journal:  BMJ       Date:  2003-03-01

2.  Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration.

Authors:  Ursula Schmidt-Erfurth; Wolf-Dieter Vogl; Lee Merrill Jampol; Hrvoje Bogunović
Journal:  Ophthalmology       Date:  2020-03-16       Impact factor: 12.079

3.  Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.

Authors:  Frank G Holz; Pravin U Dugel; Georges Weissgerber; Robin Hamilton; Rufino Silva; Francesco Bandello; Michael Larsen; Andreas Weichselberger; Andreas Wenzel; Anne Schmidt; Dominik Escher; Laura Sararols; Eric Souied
Journal:  Ophthalmology       Date:  2016-02-20       Impact factor: 12.079

4.  Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.

Authors:  Jennifer J Arnold; Anna Campain; Daniel Barthelmes; Judy M Simpson; Robyn H Guymer; Alex P Hunyor; Ian L McAllister; Rohan W Essex; Nigel Morlet; Mark C Gillies
Journal:  Ophthalmology       Date:  2015-04-04       Impact factor: 12.079

5.  Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Sumit Sharma; Cynthia A Toth; Ebenezer Daniel; Juan E Grunwald; Maureen G Maguire; Gui-Shuang Ying; Jiayan Huang; Daniel F Martin; Glenn J Jaffe
Journal:  Ophthalmology       Date:  2016-01-09       Impact factor: 12.079

Review 6.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

Authors:  Ursula Schmidt-Erfurth; Victor Chong; Anat Loewenstein; Michael Larsen; Eric Souied; Reinier Schlingemann; Bora Eldem; Jordi Monés; Gisbert Richard; Francesco Bandello
Journal:  Br J Ophthalmol       Date:  2014-09       Impact factor: 4.638

7.  Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol.

Authors:  Tiezhu Lin; Kunny C Dans; Ilkay Kilic Muftuoglu; Amit Meshi; Manuel J Amador-Patarroyo; Lingyun Cheng; William R Freeman
Journal:  Br J Ophthalmol       Date:  2019-07-13       Impact factor: 4.638

8.  The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.

Authors:  Jennifer J Arnold; Caroline M Markey; Nicol P Kurstjens; Robyn H Guymer
Journal:  BMC Ophthalmol       Date:  2016-03-24       Impact factor: 2.209

9.  Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors.

Authors:  Jakob Siedlecki; Cheryl Fischer; Benedikt Schworm; Thomas C Kreutzer; Nikolaus Luft; Karsten U Kortuem; Ricarda G Schumann; Armin Wolf; Siegfried G Priglinger
Journal:  Sci Rep       Date:  2020-05-15       Impact factor: 4.379

10.  Quantitative Optical Coherence Tomography Angiography Parameters in Type 1 Macular Neovascularization Secondary to Age-Related Macular Degeneration.

Authors:  Alessandro Arrigo; Emanuela Aragona; Carlo Di Nunzio; Francesco Bandello; Maurizio Battaglia Parodi
Journal:  Transl Vis Sci Technol       Date:  2020-08-31       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.